Luigi Bartalena

Active 1983–2025

108
Papers
19,213
Citations
79
h-index
105
i10-index

Citations

Citations per year for Luigi Bartalena1948: 3 citations1983: 1 citations1984: 1 citations1985: 1 citations1986: 1 citations1987: 2 citations1988: 2 citations1989: 7 citations1990: 4 citations1991: 11 citations1992: 10 citations1993: 16 citations1994: 21 citations1995: 5 citations1996: 13 citations1997: 24 citations1998: 38 citations1999: 15 citations2000: 61 citations2001: 76 citations2002: 67 citations2003: 69 citations2004: 71 citations2005: 48 citations2006: 59 citations2007: 75 citations2008: 92 citations2009: 79 citations2010: 74 citations2011: 86 citations2012: 149 citations2013: 100 citations2014: 109 citations2015: 57 citations2016: 106 citations2017: 47 citations2018: 104 citations2019: 400 citations2020: 489 citations2021: 396 citations2022: 418 citations2023: 326 citations2024: 465 citations2025: 255 citations2026: 6 citations1949–1982: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 526 citing papers, 18.7% of this breakdownChina: 350 citing papers, 12.5% of this breakdownItaly: 330 citing papers, 11.7% of this breakdownUnited Kingdom: 202 citing papers, 7.2% of this breakdownGermany: 187 citing papers, 6.7% of this breakdownNetherlands: 112 citing papers, 4% of this breakdownDenmark: 71 citing papers, 2.5% of this breakdownFrance: 71 citing papers, 2.5% of this breakdownSouth Korea: 57 citing papers, 2% of this breakdownSpain: 52 citing papers, 1.9% of this breakdownAustralia: 49 citing papers, 1.8% of this breakdownBelgium: 49 citing papers, 1.7% of this breakdown
0%18.7%Other 26.8%

Fields

  • Medicine86.8%
  • Biochemistry, Genetics and Molecular Biology5.7%
  • Nursing2.1%
  • Immunology and Microbiology1%
  • Neuroscience1%
  • Environmental Science0.8%
  • Other2.6%

Topics

  • Thyroid Disorders and Treatments15.9%
  • Ophthalmology and Eye Disorders15%
  • Thyroid Cancer Diagnosis and Treatment7.4%
  • Glaucoma and retinal disorders3.5%
  • Vestibular and auditory disorders3.4%
  • Pituitary Gland Disorders and Treatments3%
  • Other51.8%

Coauthors

All papers

Open in search
  1. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy

    Authors: , , , , , , , , , _ _, _ _, , , , , , , , , , , , , , , , , , , , Katharina A. Ponto, Ilaria Muller, Nicola Currò, Christoph Hintschich, Roland Gärtner, Simon H. S. Pearce, Lucy Clarke, Thomas Heiberg Brix, Dorte Bechtold, Gottfried Rudovfsky, N. Fichter, L. Pasquier, J. Meney, Francesca Menconi, Giulia Lanzolla, Gangadhara Sundar, Samantha Peiling Yung, Kostas Boboridis, Panagiotis Anagnostis, Marta Pérez López, Carlos Javier Sanchez, Maria Laura Tanda, Simone Donati, Andrea Papp, Shuren Li, Anna Jabłońska, Piotr Miśkiewicz, Jelena Juri, Maja Baretić - European Journal of Endocrinology 2021 cited by 977

  2. Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy

    Authors: , , , , - Frontiers in Endocrinology 2020 cited by 350

  3. 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism

    Authors: , , , , , - European Thyroid Journal 2018 cited by 929

  4. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

    Authors: , , , , , , , , , - European Thyroid Journal 2016 cited by 954

  5. Current concepts regarding Graves’ orbitopathy

    Authors: , - Journal of Internal Medicine 2022 cited by 182

  6. Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy

    Authors: , , , , , , , , , , , , , , , , , , , , - The Journal of Clinical Endocrinology & Metabolism 2012 cited by 363

  7. Selenium and the Course of Mild Graves' Orbitopathy

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 cited by 608

  8. Diagnosis and management of Graves disease: a global overview

    Authors: - Nature Reviews Endocrinology 2013 cited by 296

  9. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , A. Jane Dickinson, N. Fichter, László Hegedüs, Onur Konuk, Gerassimos Krassas, Carol Lane, John H. Lazarus, Dan S Morris, Maarten P. Mourits, Marco Nardi, C Neoh, Jacques Orgiazzi, Simon H. S. Pearce, Georg von Arx, Miloš Žarković - The Lancet Diabetes & Endocrinology 2018 cited by 216

  10. The interplay between thyroid and liver: implications for clinical practice

    Authors: , , , , , , , , , , , - Journal of Endocrinological Investigation 2020 cited by 177

  11. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Endocrinology 2008 cited by 797

  12. Prevalence and Natural History of Graves' Orbitopathy in a Large Series of Patients With Newly Diagnosed Graves' Hyperthyroidism Seen at a Single Center

    Authors: , , , , , , , , , , - The Journal of Clinical Endocrinology & Metabolism 2013 cited by 323

  13. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism

    Authors: , , , , , - European Thyroid Journal 2015 cited by 318

  14. A 2013 European survey of clinical practice patterns in the management of Graves' disease

    Authors: , , , - Clinical Endocrinology 2014 cited by 197

  15. Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , _ _ - European Journal of Endocrinology 2018 cited by 93

  16. Epidemiology and Prevention of Graves' Ophthalmopathy

    Authors: , - Thyroid 2002 cited by 454

  17. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction

    Authors: , , , , , - European Thyroid Journal 2018 cited by 256

  18. Management of Graves’ Ophthalmopathy: Reality and Perspectives*

    Authors: , , - Endocrine Reviews 2000 cited by 617

  19. Vitreous Substitutes: The Present and the Future

    Authors: , , , , , , , , , - BioMed Research International 2014 cited by 120

  20. Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors

    Authors: , , , - Ophthalmic Plastic and Reconstructive Surgery 2023 cited by 56

  21. Proposal for Standardization of Primary and Secondary Outcomes in Patients with Active, Moderate-to-Severe Graves’ Orbitopathy

    Authors: , - European Thyroid Journal 2020 cited by 48

  22. Extrathyroidal manifestations of Graves’ disease: a 2014 update

    Authors: , - Journal of Endocrinological Investigation 2014 cited by 277

  23. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Orphanet Journal of Rare Diseases 2017 cited by 170

  24. PREGO (presentation of Graves’ orbitopathy) study: changes in referral patterns to European Group On Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M. Bernard, Lucy Clarke, Nicola Currò, Colin Dayan, James A. Dickinson, Miroslav Knežević, Carol Lane, Claudio Marcocci, Michele Marinò, Lars Møller, Marco Nardi, Christopher Neoh, Simon H. S. Pearce, G. von Arx, Füsun Baloş Törüner - British Journal of Ophthalmology 2015 cited by 119